Cellebrite DI (CLBT) Projected to Post Earnings on Thursday

Cellebrite DI (NASDAQ:CLBT) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of $0.0616 per share and revenue of $131.8740 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Cellebrite DI Stock Up 0.8%

Cellebrite DI stock opened at $16.03 on Wednesday. Cellebrite DI has a 12-month low of $11.02 and a 12-month high of $19.98. The business’s 50-day moving average price is $14.57 and its two-hundred day moving average price is $14.09. The stock has a market cap of $4.00 billion, a PE ratio of 57.25, a P/E/G ratio of 1.97 and a beta of 1.18.

Insiders Place Their Bets

In other Cellebrite DI news, CEO Thomas E. Hogan sold 103,188 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the completion of the transaction, the chief executive officer owned 590,777 shares of the company’s stock, valued at $9,310,645.52. This represents a 14.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 157,580 shares of company stock valued at $2,471,488 in the last 90 days. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CLBT. Pertento Partners LLP grew its holdings in Cellebrite DI by 28.2% during the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock worth $107,447,000 after acquiring an additional 1,311,109 shares during the last quarter. Invesco Ltd. increased its position in Cellebrite DI by 0.8% in the 4th quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after acquiring an additional 43,041 shares during the period. Cooper Creek Partners Management LLC bought a new position in shares of Cellebrite DI during the third quarter valued at $55,999,000. Nine Ten Capital Management LLC raised its stake in shares of Cellebrite DI by 16.9% during the third quarter. Nine Ten Capital Management LLC now owns 2,479,727 shares of the company’s stock valued at $45,949,000 after acquiring an additional 358,193 shares during the last quarter. Finally, Nuveen LLC lifted its holdings in shares of Cellebrite DI by 6.0% during the fourth quarter. Nuveen LLC now owns 2,279,640 shares of the company’s stock worth $41,102,000 after purchasing an additional 130,013 shares during the period. Institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CLBT. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, DA Davidson increased their price objective on shares of Cellebrite DI from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.80.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.